REP. BLILEY (R-VA.) REPLACING REP. DINGELL AS FDA PRIME MOVER ON CAPITOL HILL; TURNOVER IN COMMITTEES WILL BE ACCOMPANIED BY DEEP CUTS IN DEMOCRATIC STAFFS
Rep. Bliley (R-Va.) -- a long-term ally of the pharmaceutical industry with a burning interest in the Kessler FDA -- appears likely to replace Rep. Dingell (D-Mich.) and/or Rep. Waxman (D- Calif.) as the Congressional overlord for FDA policy in the Republican 104th Congress.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth